WO2018074296A1 - 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 - Google Patents
低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 Download PDFInfo
- Publication number
- WO2018074296A1 WO2018074296A1 PCT/JP2017/036781 JP2017036781W WO2018074296A1 WO 2018074296 A1 WO2018074296 A1 WO 2018074296A1 JP 2017036781 W JP2017036781 W JP 2017036781W WO 2018074296 A1 WO2018074296 A1 WO 2018074296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prp
- conjugate
- molecular weight
- vaccine
- hib
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for preparing a PRP conjugate by a binding reaction between polyribosyl ribitol phosphate (PRP) and a carrier protein, and a method for producing a Haemophilus influenzae type b (Hib) conjugate vaccine.
- PRP polyribosyl ribitol phosphate
- Hib Haemophilus influenzae type b
- Haemophilus influenzae is a facultative anaerobic gram-negative bacilli, has the property of “polymorphism” in the form of filaments and cocci, and has no spores or flagella. It is classified into a non-capsular strain and a capsular strain depending on the presence or absence of the capsule, and it is known that the b-type strain (Hib), which is a capsular strain, has particularly high pathogenicity. Hib infection is a major factor in meningitis in infants, Hib bacteria colonized in the upper respiratory tract invade into the blood, spread from bacteremia to the whole body, systemic infections such as meningitis, pharyngitis, arthritis Cause illness.
- Patent Document 1 discloses a method for producing Hib and a glycoprotein conjugate and use as a combination vaccine
- Patent Document 2 discloses an improved method for producing an oligosaccharide conjugate vaccine.
- Patent Document 3 discloses a method in which a Hib strain is cultured in a medium, the supernatant is purified, and PRP is extracted.
- Tetanus toxoid is required to have a purity exceeding 1,000Lf / mgPN according to WHO standards. 31 out of 34 manufacturers worldwide have met this standard, 15 of which have been reported to achieve a purity of over 1,500 LF / mgPN (Non-patent Document 1).
- the European Pharmacopoeia (EP) standards for Hib conjugate vaccines are> 1,500Lf / mgPN.
- Tetanus toxoid purification methods include ammonium sulfate precipitation, trichloroacetic acid precipitation, column chromatography (gel filtration chromatography, affinity chromatography), salting out, dialysis, and the like.
- Patent Document 4 discloses a composite vaccine characterized in that the ratio of polysaccharide to protein is 1: 0.3 to 1: 2.
- Non-Patent Documents 2 to 4 As a method for evaluating the immunogenicity of a Hib conjugate vaccine, an immunogenicity test using rats is known, and the antibody titer is evaluated by ELISA (Enzyme-Linked ImmunoSorbent Assay).
- ELISA Enzyme-Linked ImmunoSorbent Assay
- Non-patent document 8 reports the results of preparing Hib conjugates by reductive amination method using different lengths of PRP and performing immunogenicity evaluation.
- Vaccine 14 (4) (1996) 313-320 The Journal of Infectious Diseases, 190, 1177-1182, 2004 The Journal of Infectious Diseases, 191, 58-64, 2005 Vaccine 24 (2006) 3505-3512 Vaccine 16 (1998) 1842-1849 Vaccine 19 (2001) 902-907 Vaccine 25 (2007) 194-200 Vaccine 33 (2015) 2646-2654 Infection and Immunity, 40 (1) 1983, 245-256 Biologicals 35 (2007) 235-245 Vaccine 32 (2014) 5650-5656 Vaccine 12 (8) (1994) 700-706 Journal of Pharmaceutical and Biomedical Analysis 21 (6) (2000) 1087-1091 Journal of Microbiology and Biotechnology (2003), 13 (3), 469-472
- Hib conjugate vaccines that use PRP conjugates as antigens are highly immunogenic for infants and are effective, but lower storage stability due to the release of PRP from the carrier protein during vaccine storage is an issue. . Although development of a more stable Hib conjugate vaccine is desired, an effective method for suppressing the increase in free PRP content has not been reported.
- the present invention has been made in view of the above circumstances, and provides a method for preparing a PRP conjugate excellent in storage stability and a method for producing a Hib conjugate vaccine.
- the present inventors have prepared a method for preparing a stable PRP conjugate in which an increase in free PRP content is suppressed by using PRP having a moderately lower molecular weight than native PRP. I found. Furthermore, the present inventors have energetically examined the weight ratio of the PRP and the carrier protein in the reaction, the purity of the carrier protein (especially tetanus toxoid), and the pH of the storage solution after preparation of the PRP conjugate. The present inventors have found a method for producing a more stable Hib conjugate vaccine.
- the present invention includes the following.
- [1] In a method for preparing a PRP conjugate by a coupling reaction between polyribosyl ribitol phosphate (PRP) and a carrier protein, a PRP conjugate having a molecular weight lower than that of native PRP is used. A preparation method characterized in that release of PRP from a gate is suppressed.
- the method according to [1] which comprises storing the solution in a pH of 5.4 to 6.3 after the preparation of the PRP conjugate.
- [3] The method according to [2], wherein a free PRP content is less than 50% in a severe test at 37 ° C. for 4 weeks in a solution having a pH of 5.4 to 6.3.
- the prepared PRP conjugate can be stably stored for a long period of time. Furthermore, the Hib conjugate vaccine can be stably stored while maintaining sufficient immunogenicity.
- 4 is a graph showing a relationship between an increase in free PRP content (%) and a PRP molecular weight when a PRP conjugate prepared according to an embodiment of the present invention is stored at 37 ° C. for 4 weeks.
- the immunogenicity when a rat is immunized with 1/25 SHD (Single Human Dose) and 1/50 SHD with a Hib conjugate vaccine using a PRP conjugate prepared by changing the PRP molecular weight as an antigen. It is the shown graph.
- a rat When a rat is immunized with 1/25 SHD and 1/50 SHD with a Hib conjugate vaccine using a PRP conjugate prepared by changing the weight ratio of PRP and carrier protein subjected to the binding reaction according to an embodiment of the present invention as an antigen. It is the graph which showed the immunogenicity of.
- rats were immunized with 1/100 SHD and 1/500 SHD with Hib conjugate mixed vaccine using PRP conjugate prepared by changing the weight ratio of PRP and carrier protein for the binding reaction as an antigen. It is the graph which showed the immunogenicity at the time.
- FIG. 6 is a graph showing immunogenicity when a rat is immunized three times with different doses of a Hib conjugate mixed vaccine using a PRP conjugate prepared as an antigen according to an embodiment of the present invention.
- Free PRP content when a Hib conjugate mixed vaccine containing PRP conjugate prepared by changing the weight ratio of PRP and carrier protein subjected to binding reaction according to one embodiment of the present invention as an antigen is stored at 37 ° C. for 4 weeks
- 5 is a graph showing the relationship between the increase in (%) and the storage solution pH.
- a free PRP when a Hib conjugate mixed vaccine having a PRP conjugate prepared by changing the weight ratio of PRP and carrier protein subjected to a binding reaction according to an embodiment of the present invention as an antigen is stored at 10 ° C. for 45 months It is the graph which showed the relationship between the raise of content (%), and preservation solution pH.
- a PRP having a lower molecular weight than that of native PRP is used to perform a PRP conjugate from the prepared PRP conjugate in performing a binding reaction between PRP and a carrier protein. It is characterized in that release of is suppressed.
- the Hib conjugate vaccine using the PRP conjugate obtained by this preparation method as an antigen is similarly excellent in storage stability and retains sufficient immunogenicity.
- PRP conjugates can be prepared by known binding techniques.
- PRP can be linked via a thioether bond.
- PRP is activated with 1-cyano-4- (dimethylamino) pyridine tetrafluoroborate (CDAP) to form a cyanate ester.
- CDAP 1-cyano-4- (dimethylamino) pyridine tetrafluoroborate
- the PRP activated in this way can be linked to the amino group of the carrier protein directly or via a spacer group.
- the cyanate ester is combined with hexanediamine, and the amino-derivatized polysaccharide and the carrier protein are conjugated by a heteroligation chemical reaction involving the formation of a thioether bond (Patent Document 5).
- conjugates can also be prepared by a reductive amination method (Patent Documents 6 to 9).
- Still another method is a method of binding cyanogen bromide (CNBr) activated polysaccharide derivatized with adipic acid dihydrazide (ADH) to a carrier protein by carbodiimide condensation (Non-patent Document 9).
- Carrier proteins include tetanus toxoid, pertussis toxoid, diphtheria toxoid, CRM197 which is a gene variant of diphtheria toxoid, non-capsular hemophilus influenza D antigen, meningitis group B outer membrane protein (OMP), etc. Can be mentioned.
- a typical carrier protein for PRP conjugates is tetanus toxoid.
- tetanus toxoid When using tetanus toxoid as a carrier protein, its purity should be at least 1,000 Lf / mg PN, which is the WHO standard. In the method of the present invention, the purity of tetanus toxoid is better, and it is preferably 2,500 to 3,500 Lf / mgPN. More preferably, it is 2,900-3,300 Lf / mgPN.
- crushing is performed at a pressure of 10,000 to 30,000 psi for 10 minutes to 2 hours.
- the crushing is preferably performed at a pressure of 20,000 to 30,000 psi for 10 minutes to 2 hours, more preferably at a pressure of 25,000 to 30,000 psi for 10 minutes to 2 hours.
- hydrolysis using an acid, an oxidizing agent or an alkali can also be used.
- the acid and the oxidizing agent include hydrochloric acid, sulfuric acid, and sodium periodate
- examples of the alkali include sodium hydroxide and sodium bicarbonate.
- the molecular weight of native PRP that is not low molecular weight is about 250 to 400 kDa
- the molecular weight of low molecular weight PRP is less than 250 kDa. In the present invention, it is preferably 80 to 150 kDa, more preferably 80 to 100 kDa.
- the molecular weight is measured by a method using an HPLC (High Performance Liquid Chromatography) apparatus described in Non-Patent Document 10 or Non-Patent Document 11.
- HPLC High Performance Liquid Chromatography
- the calibration curve is created using pullulan or the like, and the molecular weight of the peak top can be obtained as a converted value of pullulan or the like.
- the absolute molecular weight can be determined by a method using MALS (Multi Angle Light Scattering). Any other method that can measure the molecular weight may be used.
- PRP and carrier protein are used to avoid excessive antibody responses to the carrier protein and to increase the vaccine productivity per carrier protein by reducing the amount of carrier protein used. It is subjected to a binding reaction in a weight ratio range of 2: 1 to 4: 1. A more preferred weight ratio is 4: 1.
- the pH of the PRP conjugate storage solution is preferably 5.0 to 6.6, more preferably pH 5.4 to 6.3.
- the pH may be adjusted with an acid such as hydrochloric acid or acetic acid, an alkaline solution such as sodium hydroxide or sodium hydrogen carbonate, or a buffer solution may be used.
- the storage solution may be a phosphate buffer solution, an acetate buffer solution, a MES buffer solution, or another buffer solution such as a succinate buffer solution, as long as it can maintain the above-mentioned pH range. .
- the free PRP content can be measured by the method described in Non-Patent Documents 12-14.
- the temperature condition for the long-term storage test when examining stability is 5 ⁇ 3 ° C or 10 ° C or less avoiding freezing. Alternatively, stability may be accelerated and evaluated under higher temperature conditions.
- the immunogenicity of the Hib conjugate vaccine prepared by the method according to the present invention is determined by immunizing animals such as rats and monkeys and measuring the anti-PRP antibody titer.
- the antibody titer is measured by ELISA or the like.
- evaluation may be performed by a serum bactericidal antibody (SBA) test using complement and Hib bacteria as described in Non-Patent Document 11. Since it is known that the antibody titer and the SBA titre correlate to a certain extent as described in Non-Patent Document 11, evaluation may be performed by the antibody titer by ELISA.
- SBA serum bactericidal antibody
- the Hib conjugate vaccine produced by the method according to the present invention hardly causes immune interference, it may be a mixed vaccine with other antigens.
- examples thereof include a mixed vaccine with a precipitated purified pertussis diphtheria tetanus inactivated polio mixed vaccine.
- the Hib conjugate vaccine produced by the method according to the present invention may be used together with an adjuvant.
- the dosage form may be a liquid formulation or a lyophilized formulation.
- EDC which is a condensing agent, with activated PRP and a tetanus toxoid (TT) stock solution (produced by Chemo-Serum Therapy Laboratories) with a purity of 2,900-3,300 LF / mgPN at a weight ratio of 1: 1, 2: 1, 4: 1
- TT tetanus toxoid
- Hib conjugate vaccine 1 group of 5 SD rats (female, 5 weeks old) on the back with PRP conjugate (PRP molecular weight: Native, 155 kDa, 108 kDa, 88 kDa and those with different molecular weight of PRP, or 0.5 ml of the Hib conjugate vaccine using the antigen prepared in Example 2 by changing the weight ratio of PRP and carrier protein) was inoculated subcutaneously, and the second inoculation was performed 4 weeks later. Blood was collected 2 weeks after the second inoculation, and the antibody titer was measured by ELISA prepared in-house. The results are shown in FIGS. It was confirmed that an anti-PRP antibody titer equivalent to or higher than the existing Hib conjugate vaccine (“ActHIB (trade name)” manufactured by Sanofi Pasteur) was obtained.
- DTP-IPV 4 kinds of mixed vaccine precipitation precipitated pertussis diphtheria tetanus inactivated polio (Sabin strain) mixed vaccine; Quattrovac) (trade name) ") or sedimentation purified pertussis diphtheria tetanus mixed vaccine (manufactured by Chemo-Serum Therapeutic Institute) with inactivated poliovirus (IPV; Salk strain) added to PRP conjugate
- mixed vaccine precipitation precipitated pertussis diphtheria tetanus inactivated polio (Sabin strain) mixed vaccine; Quattrovac) (trade name)
- sedimentation purified pertussis diphtheria tetanus mixed vaccine manufactured by Chemo-Serum Therapeutic Institute
- IPV inactivated poliovirus
- PRP conjugate PRP molecular weight: Native, 155, 108, 88 kDa and PRP molecular weight changed, or PRP and carrier protein weight ratio changed on the back of 5 SD rats per group (female, 5 weeks old)
- 0.5 ml of a Hib conjugate vaccine having the antigen (prepared in Example 2) as an antigen was subcutaneously inoculated, and a second inoculation was performed 4 weeks later. Blood was collected 2 weeks after the second inoculation, and the antibody titer was measured by ELISA prepared in-house. The result is shown in FIG.
- the immunogenicity of the prepared 5 kinds of mixed vaccine was subcutaneously administered 3 times at 3 week intervals to the back of 10 rats (Wister, female, 8 weeks old) per group, and blood was collected 3 weeks after inoculation.
- the antibody titer was measured with the prepared ELISA.
- FIG. When the dose of 5 types of mixed vaccine was changed and compared with the 5 types of mixed vaccine mixed with existing Hib conjugate vaccine ("ActHIB (trade name)" manufactured by Sanofi Pasteur) The value of 10 ⁇ g was the highest in the existing Hib conjugate vaccine, whereas the value of 2 ⁇ g was the highest in the Hib conjugate vaccine of the present invention, and it was estimated that the equivalent immunogenicity could be obtained with a smaller dose. .
- the preparation method according to the present invention can be used in the manufacture of a Hib conjugate vaccine and a mixed vaccine containing a Hib conjugate vaccine.
Abstract
Description
[1]ポリリボシルリビトールリン酸(PRP)とキャリアたん白質とを結合反応によりPRPコンジュゲートを調製する方法において、ネイティブPRPよりも低分子化されたPRPを用いることにより、調製後のPRPコンジュゲートからPRPの遊離が抑制されることを特徴とする調製方法。
[2]PRPコンジュゲートの調製後、pH5.4~6.3の溶液で保存することを含む、[1]に記載の方法。
[3]pH5.4~6.3の溶液で37℃、4週間の苛酷試験における遊離PRP含量が50%未満である、[2]に記載の方法。
[4]PRPの低分子化の方法が物理的破砕である、[1]~[3]のいずれか一項に記載の方法。
[5]PRPの低分子化の方法が酸又はアルカリによる加水分解である、[1]~[3]のいずれか一項に記載の方法。
[6]低分子化したPRPの分子量が80~150kDaである、[1]~[5]のいずれか一項に記載の方法。
[7]PRPコンジュゲートを調製する結合反応において、PRPとキャリアたん白質が重量比2:1から4:1で反応に供される、[1]~[6]のいずれか一項に記載の方法。
[8]PRPとキャリアたん白質が重量比4:1で反応に供される、[7]に記載の方法。
[9]PRPコンジュゲートを調製する結合反応の前に、1-シアノ-4-(ジメチルアミノ)ピリジンテトラフルオロボレート(CDAP)を用いて、低分子化したPRPを活性化させる工程を含む、[1]~[8]のいずれか一項に記載の方法。
[10]キャリアたん白質が破傷風トキソイドである、[1]~[9]のいずれか一項に記載の方法。
[11]破傷風トキソイドの純度が2,500~3,500LF/mgPNである、[10]に記載の方法。
[12]破傷風トキソイドの純度が2,900~3,300LF/mgPNである、[11]に記載の方法。
[13][1]~[11]のいずれか一項に記載の方法を含む、ヘモフィルス・インフルエンザ菌b型菌(Hib)コンジュゲートワクチンの製造方法。
[14][13]に記載の製造方法で製造したHibコンジュゲートワクチンの、混合ワクチンとしての使用。
[15][13]に記載の製造方法で製造したHibコンジュゲートワクチンの、沈降精製百日せきジフテリア破傷風不活化ポリオ混合ワクチンとの5種混合ワクチンとしての使用。
特許文献10や11などに記載の定法に従って、NAD(Nicotinamide Adenine Dinucleotide)を加えたBHI(Brain Heart Broth)培地にて、Hibを8~14時間、37℃で培養し、上清をエタノール沈殿で精製することによりプルラン換算量でピークトップ分子量が250~400kDaの精製PRPを得た。精製PRPを含むプロセス液を高圧乳化機(Microfluidics社製)にて10,000psi、20,000psi、30,000psiの各圧力にて15~20回処理し、PRPを物理的に破砕することにより低分子化した。得られた低分子化PRPを分子サイズ分析し、ピークトップ分子量がそれぞれ155kDa、108kDa、81kDaであることを確認した。
得られた各低分子化PRPの2~12mg/mLを、100mg/mL濃度のCDAPにてPRPに対する重量比が0.2~2.0となる条件にて反応させ、さらに0.5MのADHと2時間反応させた。その後、透析を行って未反応物を除去することで活性化PRPを得た。活性化PRPと2,900~3,300LF/mgPNの純度の破傷風トキソイド(TT)原液(化学及血清療法研究所製)を、1:1、2:1、4:1の重量比で縮合剤であるEDC(1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド)と共にそれぞれ反応させた。濃度に応じて40分から4時間反応し、その後透析することで、PRP/TT比が0.48、0.77、1.0のPRPコンジュゲートを得た。
作製したPRPコンジュゲート(リン酸緩衝溶液、pH6.8)の保存安定性を、37℃の苛酷試験にて評価した。保存開始時、2週間後及び4週間後における遊離PRP含量(%)を非特許文献13に記載のDOC処理後、非特許文献10に記載のリボース試験を用いて測定した。その結果を図1に示す。低分子化していないネイティブPRPや155kDaのPRPに比べて、より低分子化した108kDaや81kDaのPRPの方が、遊離PRP含量の上昇を抑制できることが分かった。
pHが6.0、6.3、6.6、7.0であるリン酸緩衝液を調製し、PRPコンジュゲート(低分子化後PRP分子量142kDa)の保存溶液のpHによる影響を37℃の苛酷条件にて評価した。保存開始時、2週間後及び4週間後における遊離PRP含量(%)を実施例3と同様の方法を用いて測定した結果、pH6~7の範囲においてpHが低いほど、遊離PRP含量の上昇を抑えられることが分かった(表1)。
1群5匹のSDラット(メス、5週齢)の背部にPRPコンジュゲート(PRP分子量:Native、155kDa、108kDa、88kDaとPRPの分子量を変えたもの、又は、PRPとキャリアたん白質の重量比を変えて実施例2で調製したもの)を抗原とするHibコンジュゲートワクチンを、0.5mL皮下接種し、4週間後に2回目の接種を行った。2回目の接種から2週後に採血を行い、自家調製したELISAにて抗体価を測定した。その結果を図2及び図3に示す。既存のHibコンジュゲートワクチン(サノフィパスツール社製「アクトヒブ(ActHIB)(商標名)」)に比べて同等以上の抗PRP抗体価が得られていることを確認した。
DTP-IPV4種混合ワクチン(沈降精製百日せきジフテリア破傷風不活化ポリオ(セービン株)混合ワクチン;化学及血清療法研究所製「クワトロバック(Quattrovac)(商標名)」)又は沈降精製百日せきジフテリア破傷風混合ワクチン(化学及血清療法所製)に不活化ポリオウイルス(IPV;Salk株)を加えたものに、PRPコンジュゲートを加えることで5種混合ワクチンを調製した。
Hib原液の濃度とpHを変えて37℃に1週間加温して、PRPコンジュゲート原液の安定性の評価を行った。結果を表2に示す。原液の保管条件としては、高濃度の方がより安定であった。高濃度条件下でもpHは6.8よりも6.0の方が安定であった。
混合ワクチンのpHが5.0、5.4、5.7、6.0となるように緩衝液を加え、対象検体を37℃の苛酷条件で4週間加温した後、遊離PRPを測定した。結果を表3に示す。混合ワクチンのpHは6.0、5.7、5.4の方が良く、pH5.0は不安定となる結果であった。なお、混合ワクチン中のHib以外の抗原の免疫原性への影響も確認したが、pHの影響は見られなかった。
Claims (15)
- ポリリボシルリビトールリン酸(PRP)とキャリアたん白質とを結合反応によりPRPコンジュゲートを調製する方法において、ネイティブPRPよりも低分子化されたPRPを用いることにより、調製後のPRPコンジュゲートからPRPの遊離が抑制されることを特徴とする方法。
- PRPコンジュゲートの調製後、pH5.4~6.3の溶液で保存することを含む、請求項1に記載の方法。
- pH5.4~6.3の溶液で37℃、4週間の苛酷試験における遊離PRP含量が50%未満である、請求項2に記載の方法。
- PRPの低分子化の方法が物理的破砕である、請求項1~3のいずれか一項に記載の方法。
- PRPの低分子化の方法が酸又はアルカリによる加水分解である、請求項1~3のいずれか一項に記載の方法。
- 低分子化したPRPの分子量が80~150kDaである、請求項1~5のいずれか一項に記載の方法。
- PRPコンジュゲートを調製する結合反応において、PRPとキャリアたん白質が重量比2:1から4:1で反応に供される、請求項1~6のいずれか一項に記載の方法。
- PRPとキャリアたん白質が重量比4:1で反応に供される、請求項7に記載の方法。
- PRPコンジュゲートを調製する結合反応の前に、1-シアノ-4-(ジメチルアミノ)ピリジンテトラフルオロボレート(CDAP)を用いて、低分子化したPRPを活性化させる工程を含む、請求項1~8のいずれか一項に記載の方法。
- キャリアたん白質が破傷風トキソイドである、請求項1~9のいずれか一項に記載の方法。
- 破傷風トキソイドの純度が2,500~3,500LF/mgPNである、請求項10に記載の方法。
- 破傷風トキソイドの純度が2,900~3,300LF/mgPNである、請求項11に記載の方法。
- 請求項1~11のいずれか一項に記載の方法を含む、ヘモフィルス・インフルエンザb型菌(Hib)コンジュゲートワクチンの製造方法。
- 請求項13に記載の製造方法で製造したHibコンジュゲートワクチンの、混合ワクチンとしての使用。
- 請求項13に記載の製造方法で製造したHibコンジュゲートワクチンの、沈降精製百日せきジフテリア破傷風不活化ポリオ混合ワクチンとの5種混合ワクチンとしての使用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018546269A JP6944946B2 (ja) | 2016-10-20 | 2017-10-11 | 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 |
EP17863266.7A EP3530285B1 (en) | 2016-10-20 | 2017-10-11 | METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT |
CN201780064554.XA CN109922828A (zh) | 2016-10-20 | 2017-10-11 | 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法 |
US16/340,778 US11027005B2 (en) | 2016-10-20 | 2017-10-11 | Method for producing Hib conjugate vaccine using PRP with lowered molecular weight |
KR1020197013616A KR102388325B1 (ko) | 2016-10-20 | 2017-10-11 | 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016206033 | 2016-10-20 | ||
JP2016-206033 | 2016-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018074296A1 true WO2018074296A1 (ja) | 2018-04-26 |
Family
ID=62018695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/036781 WO2018074296A1 (ja) | 2016-10-20 | 2017-10-11 | 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11027005B2 (ja) |
EP (1) | EP3530285B1 (ja) |
JP (1) | JP6944946B2 (ja) |
KR (1) | KR102388325B1 (ja) |
CN (1) | CN109922828A (ja) |
TW (1) | TWI749085B (ja) |
WO (1) | WO2018074296A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022224966A1 (ja) | 2021-04-20 | 2022-10-27 | Kmバイオロジクス株式会社 | 6種混合液状ワクチン組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220072781A (ko) * | 2020-11-25 | 2022-06-02 | 주식회사 엘지화학 | 헤모필루스 인플루엔자 타입 b의 PRP 항원 정제 공정의 품질 평가 방법 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4220717A (en) | 1977-12-22 | 1980-09-02 | American Cyanamid Company | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
EP0161188A2 (en) | 1984-05-10 | 1985-11-13 | Merck & Co. Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
EP0208375A2 (en) | 1985-07-05 | 1987-01-14 | SCLAVO S.p.A. | Glycoproteinic conjugates having trivalent immunogenic activity |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
EP0477508A1 (en) | 1990-09-28 | 1992-04-01 | American Cyanamid Company | Improved oligosaccharide conjugate vaccines |
JPH07509481A (ja) * | 1992-07-31 | 1995-10-19 | エバンス バッキンズ リミテッド | 破傷風ワクチンの産生 |
JPH11507026A (ja) | 1995-06-07 | 1999-06-22 | スミスクライン・ビーチャム・バイオロジカルス (ソシエテ・アノニム) | 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン |
JP2007529503A (ja) * | 2004-03-15 | 2007-10-25 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 低用量のHib結合体との組合せワクチン |
WO2014142135A1 (ja) * | 2013-03-12 | 2014-09-18 | 武田薬品工業株式会社 | マイクロニードルパッチ |
JP2014240395A (ja) * | 2006-04-07 | 2014-12-25 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2015052684A2 (en) * | 2013-10-11 | 2015-04-16 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
JP2015522272A (ja) | 2012-07-02 | 2015-08-06 | サノフィ・パスツールSanofipasteur | ヘモフィルス・インフルエンザb型菌抗原の生成方法 |
JP2016509081A (ja) * | 2012-12-20 | 2016-03-24 | ファイザー・インク | 糖複合化方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US590649A (en) | 1897-09-28 | Sprocket wheel and chain | ||
EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
KR100208375B1 (ko) | 1995-12-27 | 1999-07-15 | 윤종용 | 동화상 부호화 방법 및 장치 |
US6309646B1 (en) * | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
US6603266B1 (en) | 1999-03-01 | 2003-08-05 | Lg Electronics Inc. | Flat-panel display |
EP1035137A1 (en) * | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
ES2341863T3 (es) * | 2003-09-11 | 2010-06-29 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Proceso para la produccion de un polisacarido capsular para su uso en vacunas de conjugado. |
KR101359930B1 (ko) * | 2004-09-22 | 2014-02-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물 |
MX2007016237A (es) * | 2005-06-27 | 2008-03-07 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
LT2384765T (lt) | 2005-12-22 | 2017-01-10 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae vakcina |
GB0616306D0 (en) * | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
AU2008248640A1 (en) * | 2007-05-02 | 2008-11-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
AU2010243827A1 (en) * | 2009-04-30 | 2011-11-17 | Optisens Gmbh | Concentrated, creamy to solid and dry compositions of an oil-in-water emulsion, method for the production thereof and use thereof for producing improved foods in terms of sensory aspects and nutrition physiology |
AU2012236880B2 (en) * | 2011-03-28 | 2016-11-17 | Geron Corporation | Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR |
KR20160062168A (ko) * | 2013-10-11 | 2016-06-01 | 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 | 증진된 면역원성을 갖는 폴리사카라이드-단백질 접합체 및 이의 신속한 고생산 방법 |
-
2017
- 2017-10-11 KR KR1020197013616A patent/KR102388325B1/ko active IP Right Grant
- 2017-10-11 EP EP17863266.7A patent/EP3530285B1/en active Active
- 2017-10-11 US US16/340,778 patent/US11027005B2/en active Active
- 2017-10-11 JP JP2018546269A patent/JP6944946B2/ja active Active
- 2017-10-11 WO PCT/JP2017/036781 patent/WO2018074296A1/ja unknown
- 2017-10-11 CN CN201780064554.XA patent/CN109922828A/zh active Pending
- 2017-10-13 TW TW106135074A patent/TWI749085B/zh active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4220717A (en) | 1977-12-22 | 1980-09-02 | American Cyanamid Company | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
EP0161188A2 (en) | 1984-05-10 | 1985-11-13 | Merck & Co. Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
EP0208375A2 (en) | 1985-07-05 | 1987-01-14 | SCLAVO S.p.A. | Glycoproteinic conjugates having trivalent immunogenic activity |
JPS6230726A (ja) | 1985-07-05 | 1987-02-09 | ビオチーネ エセ.ピー.アー. | 糖たんぱく質結合体 |
EP0477508A1 (en) | 1990-09-28 | 1992-04-01 | American Cyanamid Company | Improved oligosaccharide conjugate vaccines |
JPH06340550A (ja) | 1990-09-28 | 1994-12-13 | American Cyanamid Co | 改良されたオリゴ糖結合体ワクチン |
JPH07509481A (ja) * | 1992-07-31 | 1995-10-19 | エバンス バッキンズ リミテッド | 破傷風ワクチンの産生 |
JPH11507026A (ja) | 1995-06-07 | 1999-06-22 | スミスクライン・ビーチャム・バイオロジカルス (ソシエテ・アノニム) | 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン |
JP2007529503A (ja) * | 2004-03-15 | 2007-10-25 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 低用量のHib結合体との組合せワクチン |
JP2014240395A (ja) * | 2006-04-07 | 2014-12-25 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2015522272A (ja) | 2012-07-02 | 2015-08-06 | サノフィ・パスツールSanofipasteur | ヘモフィルス・インフルエンザb型菌抗原の生成方法 |
JP2016509081A (ja) * | 2012-12-20 | 2016-03-24 | ファイザー・インク | 糖複合化方法 |
WO2014142135A1 (ja) * | 2013-03-12 | 2014-09-18 | 武田薬品工業株式会社 | マイクロニードルパッチ |
WO2015052684A2 (en) * | 2013-10-11 | 2015-04-16 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
Non-Patent Citations (14)
Title |
---|
BIOLOGICALS, vol. 35, 2007, pages 235 - 245 |
INFECTION AND IMMUNITY, vol. 40, no. 1, 1983, pages 245 - 256 |
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 13, no. 3, 2003, pages 469 - 472 |
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 21, no. 6, 2000, pages 1087 - 1091 |
THE JOURNAL OF INFECTIOUS DISEASES, vol. 190, 2004, pages 1177 - 1182 |
THE JOURNAL OF INFECTIOUS DISEASES, vol. 191, 2005, pages 58 - 64 |
VACCINE, vol. 12, no. 8, 1994, pages 700 - 706 |
VACCINE, vol. 14, no. 4, 1996, pages 313 - 320 |
VACCINE, vol. 16, 1998, pages 1842 - 1849 |
VACCINE, vol. 19, 2001, pages 902 - 907 |
VACCINE, vol. 24, 2006, pages 3505 - 3512 |
VACCINE, vol. 25, 2007, pages 194 - 200 |
VACCINE, vol. 32, 2014, pages 5650 - 5656 |
VACCINE, vol. 33, 2015, pages 2646 - 2654 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022224966A1 (ja) | 2021-04-20 | 2022-10-27 | Kmバイオロジクス株式会社 | 6種混合液状ワクチン組成物 |
KR20230173114A (ko) | 2021-04-20 | 2023-12-26 | 케이엠 바이올로직스 가부시키가이샤 | 6종 혼합 액상 백신 조성물 |
Also Published As
Publication number | Publication date |
---|---|
EP3530285C0 (en) | 2023-08-09 |
KR20190069479A (ko) | 2019-06-19 |
US20200046822A1 (en) | 2020-02-13 |
TWI749085B (zh) | 2021-12-11 |
EP3530285A4 (en) | 2020-06-24 |
US11027005B2 (en) | 2021-06-08 |
EP3530285A1 (en) | 2019-08-28 |
EP3530285B1 (en) | 2023-08-09 |
CN109922828A (zh) | 2019-06-21 |
KR102388325B1 (ko) | 2022-04-18 |
TW201818960A (zh) | 2018-06-01 |
JP6944946B2 (ja) | 2021-10-06 |
JPWO2018074296A1 (ja) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6947789B2 (ja) | 肺炎連鎖球菌(Streptococcus pneumoniae)莢膜多糖およびそのコンジュゲート | |
TWI756893B (zh) | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 | |
TWI281403B (en) | Vaccine | |
JP7132954B2 (ja) | 改善された免疫原性及び結合活性を提供する2価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン | |
JP6884145B2 (ja) | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 | |
TW201531299A (zh) | 包含結合之莢膜醣抗原的免疫原組合物及其用途 | |
US10576138B2 (en) | Vaccines and compositions for the prevention of Salmonella infections | |
CN110225764A (zh) | 制备多糖-蛋白缀合物的方法 | |
JPH0347253B2 (ja) | ||
KR20140123553A (ko) | 면역원성 조성물 | |
JP2013504588A (ja) | 免疫原性の高いタンパク質マトリックスワクチン | |
AU2014313699A1 (en) | A bacterial vaccine and methods for manufacture thereof | |
CN113164581A (zh) | 纯化的肺炎链球菌荚膜多糖 | |
JP6944946B2 (ja) | 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 | |
EP4249061A2 (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof | |
RU2788526C2 (ru) | Композиции escherichia coli и способы их применения | |
OA20613A (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17863266 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018546269 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197013616 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017863266 Country of ref document: EP Effective date: 20190520 |